| Subject: | FDA Publishes Updated Information for Leukotriene Inhibitors |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Mon, 31 Aug 2009 - 09:00 am |
| The Food and Drug Administration (FDA) and the manufacturers of Leukotriene Inhibitors including Singulair (montelukast), Accolate (zafirlukast), Zyflo (zileuton) and Zyflo CR (zileuton extended release) have announced an update to the Precautions section of the prescribing information to include information about neuropsychiatric events reported in patients using these products. According to the FDA, neuropsychiatric events have been reported in some patients taking Singulair, Accolate, Zyflo... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
|
|
StayAlert!® Virtual Compliance Administrator™ keeps clients informed by email of any changes to Federal regulations, including Joint Commission (TJC, formerly JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG, and many more, and also provides downloadable tools to ensure compliance. StayAlert! is a premium product sold as an annual site-license subscription. With the site license, the client can sign up an unlimited number of users for the email alerts and access to the StayAlert! online regulatory library. The StayAlert! system was designed by healthcare professionals actively working in the healthcare environment, who were faced with attempting to competently provide quality care and services while "doing more with less". StayAlert! provides the answer to efficiently performing a variety of required job components from one centralized virtual location. StayAlert! improves data sharing and communications, thus reducing cost, broadening access and providing a system of documentation and follow-up. |
|
